Concurrently, a decrease in inflammation markers, notably C-reactive protein (CRP) and interleukin-6 (IL-6), implies the attenuation of chronic inflammation, potentially reducing endothelial dysfunction, thrombotic events, and organ fibrosis [4,25,26]. The gene discussed is IL6; the disease is endothelial dysfunction.